Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts New insights from AI-based imaging, B-cell biology and mRNA vaccine technology point to more ...

The University of Texas MD Anderson Cancer Center in Houston launched a clinical collaboration with Pfizer to study the use of immuno-oncology drugs to treat various solid tumors and blood cancers.

Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, ...

Cancer-induced nerve injury, a cause of chronic inflammation, may lead to immunotherapy resistance, according to a study published Aug. 20 in Nature. The research was led by teams from Houston-based ...

After nearly 100 years of development, treatments that bolster the body's immune system to fight cancer are coming of age – and saving patients' lives.

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step ...

With classic chemotherapy drugs, you know that you're going to give the chemotherapy and a day or two later, you're going to have side effects. With immunotherapy, the side effects can happen at any ...

Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality. Researchers at Rice University, in collaboration ...

A research team led by the University of Michigan College of Pharmacy and the University of Texas MD Anderson Cancer Center ...

Oncologists should consider neoadjuvant immunotherapy for patients with clinical stage III melanoma, which is a paradigm shift away from upfront surgery and adjuvant systemic therapy, according to a ...